hepatocellular%20carcinoma
HEPATOCELLULAR CARCINOMA

Hepatocellular carcinoma is malignancy that originates from the liver.

Physical signs are hepatomegaly and ascites. It is usually asymptomatic for much of its natural history.

Liver cancer is the second most common cause of cancer-related mortality worldwide & hepatocellular carcinoma accounts for >90% of liver cancers.

 

Hepatocellular%20carcinoma Management

Surveillance

  • Multiphasic cross-sectional imaging (eg CT or MRI) is the preferred method for surveillance following treatment due to its reliability in assessing arterial vascularity that is associated with increased risk of hepatocellular carcinoma recurrence following treatment
    • Test should be done every 3-6 months for 2 years, then every 6-12 months 
  • Serum alpha-fetoprotein (AFP) levels are associated with poor prognosis following treatment and should be measured every 3-6 months for 2 years, then every 6-12 months
  • In the event of disease recurrence, re-evaluation according to the initial work-up should be considered
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 02 Sep 2020
Proton beam radiotherapy (PBT) was noninferior to radiofrequency ablation (RFA) for local progression-free survival (LPFS) in patients with recurrent hepatocellular carcinoma (rHCC), in addition to showing a tolerable safety profile, according to the APROH trial presented during the 2020 digital ILC.
Elaine Soliven, 11 Sep 2020
Treatment with an FGF19 analogue aldafermin, previously known as NGM282, led to a significantly reduced liver fat content (LFC) in patients with nonalcoholic steatohepatitis (NASH), according to a study presented at ILC 2020.